Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing

Nkarta, Inc.

Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.
NKX019 is a CD19-directed CAR NK cell therapy for cancer; no specific data provided in the press release.
Slides will be posted on Nkarta's website; a replay will be available for 4 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.